SONIO
20.12.2022 09:31:44 CET | Business Wire | Press release
Sonio announces a €10M fundraising through the European Innovation Council Accelerator, the leading fund in supporting European deep-tech companies. For this cohort, among 1092 projects submitted, only 78 companies were selected by the EIC Accelerator. This fundraising (€2.5M in grant and €7.5M in equity investment) comes in addition to the €5M previously raised with Elaia, OneRagtime and Bpi France in June 2022. It will support Sonio, a company that empowers fetal medicine professionals and secures pregnancy ultrasounds through AI, to accelerate the release of new features on the platform, such as embedded image recognition and genomics. A great opportunity, also, to gain momentum for the French startup’s market entry in the USA, as well as ramp up sales in Europe and India.
Sonio brings together unique expertise from the fields of fetal medicine, artificial intelligence, software development and ultrasound imaging to address the 50% of congenital malformations that are not detected before birth and improve access and quality of care for pregnant women and children. Created only a couple of years ago, the startup company leverages 5 years of R&D and clinical development at Ecole Polytechnique, the PRAIRIE Institute and Necker Hospital in Paris. It already provides a comprehensive solution to assist all fetal ultrasound practitioners, from beginners to the most seasoned experts and is already being used by over 250 healthcare professionals.
“Receiving such a significant funding from one of the most competitive accelerators in the world is a testament to the innovation Sonio brings to fetal medicine” said Cécile Brosset, Chief Executive Officer and co-Founder of Sonio. « Our hard work has been fruitful. I am now more confident than ever that we can help secure pregnancy care worldwide with collective and artificial intelligence.”
“For us this funding means more research, more clinical studies, more innovation, more patents filed in Europe and ultimately an improved quality of care for patients, wherever they are. We are eager to intensify our scientific partnerships with some of the best experts in Fetal Medicine and Artificial Intelligence.” said Rémi Besson, Chief Scientific Officer and co-Founder of Sonio.
Inspired by the company’s mission and in just 2.5 years, Sonio’s multidisciplinary team has already brought 2 products to market:
- Sonio Diagnostics, designed for expert diagnostic ultrasounds, was CE marked and found its first clients in record time.
- Sonio Pro, tailored to secure and bring more efficiency to routine pregnancy ultrasounds, was launched in October and has already convinced customers in Europe.
Several partnerships have already been signed, with Samsung France, one of the main women’s health ultrasound manufacturers, but also with specialized distributors (Lifecell in India, Manager Systems in Brazil, Dynamic Medicals in Nigeria).
“This funding from EIC will allow us to accelerate our commercial development in the USA and in Europe, thanks to faster innovation and better market access. We will also be able to initiate more distribution partnerships in countries where access to healthcare is scarce, thus helping us to fulfill our mission, which is to improve access and quality of care of women and children.” said Dagmar Nuber, Chief Business Officer and co-Founder at Sonio.
About Sonio
Founded in 2020, Sonio is the only SaaS platform that empowers healthcare professionals to secure prenatal care by combining technological innovation, medical expertise, and collective intelligence. It provides a unique Artificial Intelligence software that associates the knowledge of prenatal medicine practitioners with all types of medical, imaging, genetic and environmental data to optimize prenatal screening and diagnosis.
Created by a team of entrepreneurs, and scientific, medical and tech experts, Sonio is already used by over 250 healthcare professionals.
Sonio is committed to become an “Entreprise à Mission” – a company whose objectives in the social, societal, and environmental fields are aligned with this purpose and set out in its by-laws, as defined by the 2019 PACTE law.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005108/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boomi Appoints Mike Hickman as Chief Financial Officer24.9.2026 15:00:00 CEST | Press release
Three-decade technology finance leader joins Boomi to scale global operations, bringing experience across IPO, take-private, and large-scale acquisition integration Boomi, the data activation company for AI, today announced the appointment of Mike Hickman as Chief Financial Officer. Hickman will lead Boomi's global finance and accounting organization, spanning financial planning and analysis, accounting, treasury, tax, and financial reporting. He reports to Boomi Chairman and Chief Executive Officer Steve Lucas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260924761566/en/ Boomi Appoints Mike Hickman as Chief Financial Officer Hickman brings three decades of senior finance leadership in high-growth SaaS and technology companies, with experience across the full corporate lifecycle: scaling through IPO, executing a take-private, and integrating large acquisitions. He joins from Proofpoint, where he spent seven and a half yea
Altasciences Supports 4B Healthcare in Advancing Steroid Nasal Irrigation Rinse to Clinical Trials24.9.2026 14:40:00 CEST | Press release
Altasciences is proud to announce that recent formulation work supporting 4B Healthcare Inc. (“4B”) has helped advance its RhineX nasal irrigation rinse therapy into clinical investigation. Following several months of formulation development, R&D manufacturing, stability testing, and quality assurance support at Altasciences’ CDMO facility in Harleysville, PA, the Tennessee-based pharmaceutical company has received FDA clearance to proceed with clinical testing of RhineX under its IND. First subject dosing is planned for October 2026, approximately seven months after formulation development began. "The concept for RhineX grew out of a problem I have seen in my own ENT practice for years—the need for a better treatment option for allergic rhinitis when conventional medical therapy is not enough,” said Brannon Mangus, MD, Co-Founder and CEO of 4B. “We founded 4B Healthcare to take that physician insight and turn it into a pharmaceutical product that could meaningfully change how these pa
ParaScript Acquired by Stakk to Create a Global Digital Trust Platform Focused on Combating Fraud24.9.2026 14:30:00 CEST | Press release
ParaScript’s AI-powered document intelligence technology integrates with Stakk’s SaaS platform to provide regulated organizations with a stronger defense against AI-driven digital identity fraud.Complementary technologies establish digital trust by continuously assessing identity, documents, behavior and context, making explainable decisions in milliseconds.Combined businesses serve more than 300 enterprise customers and processes more than 110 billion digital interactions annually across the U.S., Europe, the Middle East and Australia. ParaScript, an Al-powered document processing company, today announced that Stakk Limited (ASX: SKK) (“Stakk”), a company publicly traded on the Australian Stock Exchange (ASX), has successfully completed its US$63 million (A$88.7 million) acquisition of ParaScript, LLC and ParaScript Management, Inc. (“ParaScript”), creating a scaled and profitable AI-native digital trust platform. Stakk acquired ParaScript for its industry-leading AI-powered document
SLB Awarded Four Multi-Year Integrated Well Construction Contracts by Aramco24.9.2026 14:04:00 CEST | Press release
Awards expand deployment of SLB's integrated well construction model across Saudi Arabia’s oil and gas reservoirs Global energy technology company SLB (NYSE: SLB) today announced it has been awarded four integrated well construction contracts by Aramco to support oil and gas development across the Kingdom of Saudi Arabia. Under the contracts, SLB will manage end-to-end well construction services, delivering more than 450 wells in the three-year term, with an optional extension of up to two years. "Delivering hundreds of wells across a multi-year program and in multiple operating environments requires an integrated model that connects planning, execution, and digital workflows to set new industry performance benchmarks,” said Steve Gassen, executive vice president of Geographies for SLB. “Awarding SLB these advanced well construction programs at scale reflects Aramco’s confidence in our integrated model and capabilities." SLB's integrated well construction model brings together every as
Sahajanand Medical Technologies Receives EU MDR Certification for Supraflex Cruz and Product Family, Reinforcing Global Compliance and Patient Safety24.9.2026 14:03:00 CEST | Press release
Sahajanand Medical Technologies Limited (SMT), a leading global manufacturer of cardiovascular medical devices, today announced that it has received certification under the European Union Medical Device Regulation (EU MDR 2017/745) for Supraflex Cruz and its product family. SMT is a leading player in India’s drug-eluting stent market and ranks among the top five companies in key European markets, including Germany, Spain and Poland. The certification follows the conformity assessment process established under EU MDR 2017/745 including assessment of SMT’s technical documentation, clinical evaluation and quality management system. Together with SMT’s existing ISO 13485 quality management system and MDSAP certifications, the EU MDR certification confirms that Supraflex Cruz has successfully undergone assessment against the EU MDR’s stringent requirements for safety, performance and clinical evidence. Supraflex Cruz is a sirolimus-eluting coronary stent system designed to improve luminal d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom